-
1
-
-
0035467993
-
Global cancer statistics in the year 2000
-
Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2 (9): 533-43
-
(2001)
Lancet Oncol
, vol.2
, Issue.9
, pp. 533-543
-
-
Parkin, D.M.1
-
3
-
-
1642468240
-
Long term survivors of metastatic colorectal cancer treated with chemotherapy only: A North Central Cancer Treatment Group review
-
abstract no. 693
-
Hobday TJ, Cha SS, Sargent DJ, et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a North Central Cancer Treatment Group review [abstract no. 693]. Proc Am Soc Clin Oncol 2002; 21
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Hobday, T.J.1
Cha, S.S.2
Sargent, D.J.3
-
5
-
-
0027461840
-
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
-
Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306 (6880): 752-5
-
(1993)
BMJ
, vol.306
, Issue.6880
, pp. 752-755
-
-
Scheithauer, W.1
Rosen, H.2
Kornek, G.V.3
-
6
-
-
0028945766
-
Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer
-
Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6 (3): 267-74
-
(1995)
Ann Oncol
, vol.6
, Issue.3
, pp. 267-274
-
-
Glimelius, B.1
Hoffman, K.2
Graf, W.3
-
7
-
-
0034596549
-
Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis: Colorectal Cancer Collaborative Group
-
Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis: Colorectal Cancer Collaborative Group. BMJ 2000; 321 (7260): 531-5
-
(2000)
BMJ
, vol.321
, Issue.7260
, pp. 531-535
-
-
Simmonds, P.C.1
-
8
-
-
33745464490
-
Fluorinated pyrimidines: A new class of tumor inhibitory compounds
-
Heidelberger C, Chanakar NK, Danenberg PV, et al. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 1957; 179: 663-6
-
(1957)
Nature
, vol.179
, pp. 663-666
-
-
Heidelberger, C.1
Chanakar, N.K.2
Danenberg, P.V.3
-
9
-
-
0026721532
-
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate: Advanced Colorectal Cancer Meta-Analysis Project
-
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate: Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10 (6): 896-903
-
(1992)
J Clin Oncol
, vol.10
, Issue.6
, pp. 896-903
-
-
-
10
-
-
0024347268
-
Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
-
Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7 (10): 1407-18
-
(1989)
J Clin Oncol
, vol.7
, Issue.10
, pp. 1407-1418
-
-
Poon, M.A.1
O'Connell, M.J.2
Moertel, C.G.3
-
11
-
-
33947093786
-
Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism
-
Danenberg PV, Danenberg KD. Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 1978; 17: 4018-24
-
(1978)
Biochemistry
, vol.17
, pp. 4018-4024
-
-
Danenberg, P.V.1
Danenberg, K.D.2
-
12
-
-
0026006962
-
Biochemical modulation of fluorouracil with leucovorin: Confimratory evidence of improved therapeutic efficacy in advanced colorectal cancer
-
Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confimratory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9 (11): 1967-72
-
(1991)
J Clin Oncol
, vol.9
, Issue.11
, pp. 1967-1972
-
-
Poon, M.A.1
O'Connell, M.J.2
Wieand, H.S.3
-
13
-
-
1642508983
-
Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-anaysis based on 2,571 patients
-
abstract no. 1180
-
Piedbois P, Michiels S, for the Meta-Analysis Group in Cancer: survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: an updated meta-anaysis based on 2,571 patients [abstract no. 1180]. Proc Am Soc Clin Oncol 2003; 22: 294
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 294
-
-
Piedbois, P.1
Michiels, S.2
-
14
-
-
0030931974
-
A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
-
Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer 1997; 80 (7): 1179-87
-
(1997)
Cancer
, vol.80
, Issue.7
, pp. 1179-1187
-
-
Machover, D.1
-
15
-
-
0029813416
-
Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial: Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1
-
Jager E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial: Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996; 14 (8): 2274-9
-
(1996)
J Clin Oncol
, vol.14
, Issue.8
, pp. 2274-2279
-
-
Jager, E.1
Heike, M.2
Bernhard, H.3
-
16
-
-
0028175144
-
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
-
Buroker TR, O'Connell M, Wieand HS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14-20
-
(1994)
J Clin Oncol
, vol.12
, pp. 14-20
-
-
Buroker, T.R.1
O'Connell, M.2
Wieand, H.S.3
-
17
-
-
0028219974
-
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer: Advanced Colorectal Cancer Meta-Analysis Project
-
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer: Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994; 12 (5): 960-9
-
(1994)
J Clin Oncol
, vol.12
, Issue.5
, pp. 960-969
-
-
-
18
-
-
0027520967
-
Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in paients with advanced symptomatic colorectal cancer: The Nordic Gastrointestinal Tumor Adjuvant Therapy Group
-
Glimelius B. Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in paients with advanced symptomatic colorectal cancer: the Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Ann Oncol 1993; 4 (3): 235-40
-
(1993)
Ann Oncol
, vol.4
, Issue.3
, pp. 235-240
-
-
Glimelius, B.1
-
19
-
-
0026642174
-
Leucovorin enhances cytotoxicity of tremetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells
-
Romanini A, Li WW, Colofiore JR, et al. Leucovorin enhances cytotoxicity of tremetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. J Natl Cancer Inst 1992; 84: 1033-8
-
(1992)
J Natl Cancer Inst
, vol.84
, pp. 1033-1038
-
-
Romanini, A.1
Li, W.W.2
Colofiore, J.R.3
-
20
-
-
0031056423
-
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer
-
Blanke CD, Kasimis B, Schein P, et al. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997; 15: 915-20
-
(1997)
J Clin Oncol
, vol.15
, pp. 915-920
-
-
Blanke, C.D.1
Kasimis, B.2
Schein, P.3
-
21
-
-
0036227995
-
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer
-
Blanke CD, Shultz J, Cox J, et al. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol 2002; 13 (1): 87-91
-
(2002)
Ann Oncol
, vol.13
, Issue.1
, pp. 87-91
-
-
Blanke, C.D.1
Shultz, J.2
Cox, J.3
-
22
-
-
0036231984
-
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: Final results of a randomised European study
-
Punt CJ, Keizer HJ, Douma J, et al. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol 2002; 13 (1): 81-6
-
(2002)
Ann Oncol
, vol.13
, Issue.1
, pp. 81-86
-
-
Punt, C.J.1
Keizer, H.J.2
Douma, J.3
-
23
-
-
0017177398
-
Pharmacokinetics of the fluoropyrimidines: Implications for their clinical use
-
Myers CE, Diasio RB, Eliot HM, et al. Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. Cancer Treat Rev 1975; 3: 175-83
-
(1975)
Cancer Treat Rev
, vol.3
, pp. 175-183
-
-
Myers, C.E.1
Diasio, R.B.2
Eliot, H.M.3
-
24
-
-
0344109583
-
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer: Meta-Analysis Group in Cancer
-
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer: Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16 (1): 301-8
-
(1998)
J Clin Oncol
, vol.16
, Issue.1
, pp. 301-308
-
-
-
25
-
-
0026637845
-
Novel mechanism (s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
-
Aschele C, Sobrero A, Faderan MA, et al. Novel mechanism (s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52 (7): 1855-64
-
(1992)
Cancer Res
, vol.52
, Issue.7
, pp. 1855-1864
-
-
Aschele, C.1
Sobrero, A.2
Faderan, M.A.3
-
26
-
-
0031019918
-
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
-
de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15 (2): 808-15
-
(1997)
J Clin Oncol
, vol.15
, Issue.2
, pp. 808-815
-
-
De Gramont, A.1
Bosset, J.F.2
Milan, C.3
-
27
-
-
0024598566
-
Continuous low-dose infusion of fluorouracil: Is the benefit worth the cost
-
Macdonald JS. Continuous low-dose infusion of fluorouracil: is the benefit worth the cost. J Clin Oncol 1989; 7 (4): 412-4
-
(1989)
J Clin Oncol
, vol.7
, Issue.4
, pp. 412-414
-
-
Macdonald, J.S.1
-
28
-
-
0000419696
-
A simplified bimonthly regimen with leucovorin and 5FU for metastatic colorectal cancer
-
abstract no. 274
-
Tournigand C, de Gramont A, Louvet C, et al. A simplified bimonthly regimen with leucovorin and 5FU for metastatic colorectal cancer [abstract no. 274]. Proc Am Soc Clin Oncol 1998; 17
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Tournigand, C.1
De Gramont, A.2
Louvet, C.3
-
29
-
-
0345403552
-
Effective biomodulation by leucovorin of high dose infusional fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
-
Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leucovorin of high dose infusional fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 418-26
-
(1998)
J Clin Oncol
, vol.16
, pp. 418-426
-
-
Kohne, C.H.1
Schoffski, P.2
Wilke, H.3
-
30
-
-
1642468238
-
A phase III multicenter randomized study in advanced colorectal cancer: Weekly high dose continuous infusion fluorouracil versus fluorouracil plus leucovorin
-
Aranda E, Diaz-Rubio E, Cervantes A, et al. A phase III multicenter randomized study in advanced colorectal cancer: weekly high dose continuous infusion fluorouracil versus fluorouracil plus leucovorin. Ann Oncol 1988; 9: 727-31
-
(1988)
Ann Oncol
, vol.9
, pp. 727-731
-
-
Aranda, E.1
Diaz-Rubio, E.2
Cervantes, A.3
-
31
-
-
0024539308
-
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study
-
Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-32
-
(1989)
J Clin Oncol
, vol.7
, pp. 425-432
-
-
Lokich, J.J.1
Ahlgren, J.D.2
Gullo, J.J.3
-
32
-
-
0032127244
-
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
-
Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-81
-
(1998)
Eur J Cancer
, vol.34
, pp. 1274-1281
-
-
Miwa, M.1
Ura, M.2
Nishida, M.3
-
33
-
-
0035871538
-
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
-
Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19 (8): 2282-92
-
(2001)
J Clin Oncol
, vol.19
, Issue.8
, pp. 2282-2292
-
-
Hoff, P.M.1
Ansari, R.2
Batist, G.3
-
34
-
-
0035503151
-
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
-
Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19 (21): 4097-106
-
(2001)
J Clin Oncol
, vol.19
, Issue.21
, pp. 4097-4106
-
-
Van Cutsem, E.1
Twelves, C.2
Cassidy, J.3
-
35
-
-
0036731818
-
Multicenter phase III study of uracil/tegafur and oral leucovin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
-
Douillard JY, Hoff PM, Skillings J, et al. Multicenter phase III study of uracil/tegafur and oral leucovin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20 (17): 3605-16
-
(2002)
J Clin Oncol
, vol.20
, Issue.17
, pp. 3605-3616
-
-
Douillard, J.Y.1
Hoff, P.M.2
Skillings, J.3
-
36
-
-
0036727089
-
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucorin in patients with previously untreated metastatic colorectal cancer
-
Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20 (17): 3617-27
-
(2002)
J Clin Oncol
, vol.20
, Issue.17
, pp. 3617-3627
-
-
Carmichael, J.1
Popiela, T.2
Radstone, D.3
-
37
-
-
0033774136
-
Preclinical development of eniluracil: Enhancing the therapeutic index and dosing convenience of 5-fluorouracil
-
Paff M, Baccanari D, Davis ST, et al. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil. Invest New Drugs 2000; 18: 365-71
-
(2000)
Invest New Drugs
, vol.18
, pp. 365-371
-
-
Paff, M.1
Baccanari, D.2
Davis, S.T.3
-
38
-
-
0003300519
-
International phase III study of oral eniluracil plus 5-fluorouracil versus intravenous 5-FU plus LV in the treatment of advanced colorectal cancer
-
abstract no. 523
-
Van Cutsem E, Sorensen JI, Cassidy J, et al. International phase III study of oral eniluracil plus 5-fluorouracil versus intravenous 5-FU plus LV in the treatment of advanced colorectal cancer [abstract no. 523]. Proc Am Soc Clin Oncol 2001; 20
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
-
-
Van Cutsem, E.1
Sorensen, J.I.2
Cassidy, J.3
-
39
-
-
18244414936
-
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
-
van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18 (14): 2772-9
-
(2000)
J Clin Oncol
, vol.18
, Issue.14
, pp. 2772-2779
-
-
Van Groeningen, C.J.1
Peters, G.J.2
Schornagel, J.H.3
-
40
-
-
0037430037
-
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer
-
Van den Brande J, Schoffski P, Schellens JH, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 2003; 88 (5): 648-53
-
(2003)
Br J Cancer
, vol.88
, Issue.5
, pp. 648-653
-
-
Van Den Brande, J.1
Schoffski, P.2
Schellens, J.H.3
-
41
-
-
9044245305
-
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
-
Zalcberg JR, Cunningham D, van Cutsem E. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14: 716-21
-
(1996)
J Clin Oncol
, vol.14
, pp. 716-721
-
-
Zalcberg, J.R.1
Cunningham, D.2
Van Cutsem, E.3
-
42
-
-
5544237608
-
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer: 'Tomudex' Colorectal Cancer Study Group
-
Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer: 'Tomudex' Colorectal Cancer Study Group. Ann Oncol 1996; 7 (9): 961-5
-
(1996)
Ann Oncol
, vol.7
, Issue.9
, pp. 961-965
-
-
Cunningham, D.1
Zalcberg, J.R.2
Rath, U.3
-
43
-
-
0031671255
-
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer: Tomudex Colorectal Cancer Study Group
-
Cocconi G, Cunningham D, van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer: Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16: 2943-52
-
(1998)
J Clin Oncol
, vol.16
, pp. 2943-2952
-
-
Cocconi, G.1
Cunningham, D.2
Van Cutsem, E.3
-
44
-
-
0031888857
-
Mature results from three large controlled studies with raltirexted ('Tomudex')
-
Cunningham D. Mature results from three large controlled studies with raltirexted ('Tomudex'). Br J Cancer 1998; 77 Suppl. 2: 15-21
-
(1998)
Br J Cancer
, vol.77
, Issue.2 SUPPL.
, pp. 15-21
-
-
Cunningham, D.1
-
45
-
-
0033589526
-
Safety of raltitrexed
-
Ford HER, Cunningham D. Safety of raltitrexed. Lancet 1999; 354: 1824-5
-
(1999)
Lancet
, vol.354
, pp. 1824-1825
-
-
Ford, H.E.R.1
Cunningham, D.2
-
46
-
-
0002639092
-
Qualitative and chronological assessment of toxicities during treatment with raltitrexed (Tomudex) in 861 patients: Implications for patient management
-
abstract no. 222
-
Garcia-Vargas JE, Sahmoud T, Smith MP, et al. Qualitative and chronological assessment of toxicities during treatment with raltitrexed (Tomudex) in 861 patients: implications for patient management [abstract no. 222]. Eur J Cancer 1999; 35 Suppl. 4: S72
-
(1999)
Eur J Cancer
, vol.35
, Issue.4 SUPPL.
-
-
Garcia-Vargas, J.E.1
Sahmoud, T.2
Smith, M.P.3
-
47
-
-
0037018765
-
Comparison of survival, palliation, and quality of life with three chemotherapy regiments in metastatic colorectal cancer: A multicentre randomised trial
-
Maughan TS, James RD, Kerr DJ, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regiments in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359: 1555-63
-
(2002)
Lancet
, vol.359
, pp. 1555-1563
-
-
Maughan, T.S.1
James, R.D.2
Kerr, D.J.3
-
48
-
-
34548470595
-
Drug-company decision to end cancer trial
-
Drug-company decision to end cancer trial [editorial]. Lancet 1999; 354: 1045
-
(1999)
Lancet
, vol.354
, pp. 1045
-
-
-
49
-
-
0032693973
-
Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
-
Cripps C, Burnell M, Jolivet J, et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999; 10 (10): 1175-9
-
(1999)
Ann Oncol
, vol.10
, Issue.10
, pp. 1175-1179
-
-
Cripps, C.1
Burnell, M.2
Jolivet, J.3
-
50
-
-
0034655141
-
Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study
-
John W, Picus J, Blanke CD, et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000; 88 (8): 1807-13
-
(2000)
Cancer
, vol.88
, Issue.8
, pp. 1807-1813
-
-
John, W.1
Picus, J.2
Blanke, C.D.3
-
51
-
-
0029029436
-
Topoisomerase I related parameters and camptothecin activity in the colon carcinoma cell lines from the national cancer institute anticancer screen
-
Goldwasser F, Bae I, Valentini M, et al. Topoisomerase I related parameters and camptothecin activity in the colon carcinoma cell lines from the national cancer institute anticancer screen. Cancer Res 1995; 55: 2116-21
-
(1995)
Cancer Res
, vol.55
, pp. 2116-2121
-
-
Goldwasser, F.1
Bae, I.2
Valentini, M.3
-
52
-
-
0029758307
-
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity
-
McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996; 74: 508-12
-
(1996)
Br J Cancer
, vol.74
, pp. 508-512
-
-
McLeod, H.L.1
Keith, W.N.2
-
53
-
-
0028033906
-
Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors
-
Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994; 12: 530-42
-
(1994)
Cancer Invest
, vol.12
, pp. 530-542
-
-
Pommier, Y.1
Leteurtre, F.2
Fesen, M.R.3
-
54
-
-
0003293866
-
High thymidylate expression does not preclude activity of CPT-11 in colon cancer
-
abstract no. 1080
-
Saltz L, Danenberg K, Paty BP, et al. High thymidylate expression does not preclude activity of CPT-11 in colon cancer [abstract no. 1080]. Proc Am Soc Clin Oncol 1998; 17
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Saltz, L.1
Danenberg, K.2
Paty, B.P.3
-
55
-
-
0029741368
-
Involvement of β-glucuoronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivativeirinotecan hydrochloride (CPT-11) in rats
-
Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of β-glucuoronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivativeirinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-7
-
(1996)
Cancer Res
, vol.56
, pp. 3752-3757
-
-
Takasuna, K.1
Hagiwara, T.2
Hirohashi, M.3
-
56
-
-
0031014627
-
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
-
Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15 (1): 251-60
-
(1997)
J Clin Oncol
, vol.15
, Issue.1
, pp. 251-260
-
-
Rougier, P.1
Bugat, R.2
Douillard, J.Y.3
-
57
-
-
0032585197
-
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
-
Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1407-12
-
(1998)
Lancet
, vol.352
, Issue.9138
, pp. 1407-1412
-
-
Rougier, P.1
Van Cutsem, E.2
Bajetta, E.3
-
58
-
-
0032585232
-
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
-
Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352 (9138): 1413-8
-
(1998)
Lancet
, vol.352
, Issue.9138
, pp. 1413-1418
-
-
Cunningham, D.1
Pyrhonen, S.2
James, R.D.3
-
59
-
-
0029919598
-
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
-
Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14 (3): 709-15
-
(1996)
J Clin Oncol
, vol.14
, Issue.3
, pp. 709-715
-
-
Conti, J.A.1
Kemeny, N.E.2
Saltz, L.B.3
-
60
-
-
0030818926
-
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
-
Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15 (8): 2910-9
-
(1997)
J Clin Oncol
, vol.15
, Issue.8
, pp. 2910-2919
-
-
Pitot, H.C.1
Wender, D.B.2
O'Connell, M.J.3
-
61
-
-
0033198035
-
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
-
GERCOR
-
Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35 (9): 1343-7
-
(1999)
Eur J Cancer
, vol.35
, Issue.9
, pp. 1343-1347
-
-
Andre, T.1
Louvet, C.2
Maindrault-Goebel, F.3
-
62
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
-
Irinotecan Study Group
-
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343 (13): 905-14
-
(2000)
N Engl J Med
, vol.343
, Issue.13
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
-
63
-
-
0034712536
-
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
-
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355 (9209): 1041-7
-
(2000)
Lancet
, vol.355
, Issue.9209
, pp. 1041-1047
-
-
Douillard, J.Y.1
Cunningham, D.2
Roth, A.D.3
-
64
-
-
0035135378
-
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard
-
Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001; 6 (1): 81-91
-
(2001)
Oncologist
, vol.6
, Issue.1
, pp. 81-91
-
-
Saltz, L.B.1
Douillard, J.Y.2
Pirotta, N.3
-
65
-
-
0036895122
-
Early detection of toxicity and adjustment of ongoing clinical trials: The history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program
-
Goldberg RM, Sargent DJ, Morton RF, et al. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J Clin Oncol 2002; 20 (23): 4591-6
-
(2002)
J Clin Oncol
, vol.20
, Issue.23
, pp. 4591-4596
-
-
Goldberg, R.M.1
Sargent, D.J.2
Morton, R.F.3
-
66
-
-
0035849938
-
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer
-
Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345 (2): 144-5
-
(2001)
N Engl J Med
, vol.345
, Issue.2
, pp. 144-145
-
-
Sargent, D.J.1
Niedzwiecki, D.2
O'Connell, M.J.3
-
67
-
-
0035884212
-
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel
-
Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19 (18): 3801-7
-
(2001)
J Clin Oncol
, vol.19
, Issue.18
, pp. 3801-3807
-
-
Rothenberg, M.L.1
Meropol, N.J.2
Poplin, E.A.3
-
68
-
-
0024373787
-
Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): New experimental data
-
Tashiro T, Kawada Y, Sakurai Y, et al. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): new experimental data. Biomed Pharmacother 1989; 43 (4): 251-60
-
(1989)
Biomed Pharmacother
, vol.43
, Issue.4
, pp. 251-260
-
-
Tashiro, T.1
Kawada, Y.2
Sakurai, Y.3
-
69
-
-
0024407292
-
Oxalato-platinum or 1-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
-
Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989; 43 (4): 237-50
-
(1989)
Biomed Pharmacother
, vol.43
, Issue.4
, pp. 237-250
-
-
Mathe, G.1
Kidani, Y.2
Segiguchi, M.3
-
70
-
-
0031864830
-
Oxaliplatin: Mechanism of action and antineoplastic activity
-
Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25 (2 Suppl. 5): 4-12
-
(1998)
Semin Oncol
, vol.25
, Issue.2 SUPPL. 5
, pp. 4-12
-
-
Raymond, E.1
Faivre, S.2
Woynarowski, J.M.3
-
71
-
-
0037010085
-
Oxaliplatin-related side effects: Characteristics and management
-
Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29 (5 Suppl. 15): 11-20
-
(2002)
Semin Oncol
, vol.29
, Issue.5 SUPPL. 15
, pp. 11-20
-
-
Cassidy, J.1
Misset, J.L.2
-
72
-
-
0037010088
-
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures
-
Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29 (5 Suppl. 15): 21-33
-
(2002)
Semin Oncol
, vol.29
, Issue.5 SUPPL. 15
, pp. 21-33
-
-
Gamelin, E.1
Gamelin, L.2
Bossi, L.3
-
73
-
-
0025020085
-
Phase I study of oxaliplatin in patients with advanced cancer
-
Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25 (4): 299-303
-
(1990)
Cancer Chemother Pharmacol
, vol.25
, Issue.4
, pp. 299-303
-
-
Extra, J.M.1
Espie, M.2
Calvo, F.3
-
74
-
-
0022910291
-
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (1-OHP)
-
Mathe G, Kidani Y, Triana K, et al. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (1-OHP). Biomed Pharmacother 1986; 40 (10): 372-6
-
(1986)
Biomed Pharmacother
, vol.40
, Issue.10
, pp. 372-376
-
-
Mathe, G.1
Kidani, Y.2
Triana, K.3
-
75
-
-
0031840201
-
Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer
-
Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 1998; 25 (2 Suppl. 5): 23-31
-
(1998)
Semin Oncol
, vol.25
, Issue.2 SUPPL. 5
, pp. 23-31
-
-
Becouarn, Y.1
Rougier, P.2
-
76
-
-
0004700371
-
Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
-
Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9 (1): 105-8
-
(1998)
Ann Oncol
, vol.9
, Issue.1
, pp. 105-108
-
-
Diaz-Rubio, E.1
Sastre, J.2
Zaniboni, A.3
-
77
-
-
0012797224
-
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
-
Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7 (1): 95-8
-
(1996)
Ann Oncol
, vol.7
, Issue.1
, pp. 95-98
-
-
Machover, D.1
Diaz-Rubio, E.2
De Gramont, A.3
-
78
-
-
0031774842
-
Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
-
Andre T, Louvet C, Raymond E, et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9 (11): 1251-3
-
(1998)
Ann Oncol
, vol.9
, Issue.11
, pp. 1251-1253
-
-
Andre, T.1
Louvet, C.2
Raymond, E.3
-
79
-
-
0033874892
-
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
-
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16): 2938-47
-
(2000)
J Clin Oncol
, vol.18
, Issue.16
, pp. 2938-2947
-
-
De Gramont, A.1
Figer, A.2
Seymour, M.3
-
80
-
-
0033989203
-
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
-
Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18 (1): 136-47
-
(2000)
J Clin Oncol
, vol.18
, Issue.1
, pp. 136-147
-
-
Giacchetti, S.1
Perpoint, B.2
Zidani, R.3
-
81
-
-
0036499136
-
Phase II trial of chronomodulated infusion of high-dose fluorouracil and 1-folinic acid in previously untreated patients with metastatic colorectal cancer
-
Cure H, Chevalier V, Adenis A, et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and 1-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 2002; 20 (5): 1175-81
-
(2002)
J Clin Oncol
, vol.20
, Issue.5
, pp. 1175-1181
-
-
Cure, H.1
Chevalier, V.2
Adenis, A.3
-
82
-
-
0041055512
-
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy
-
Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy. Lancet 1997; 350 (9079): 681-6
-
(1997)
Lancet
, vol.350
, Issue.9079
, pp. 681-686
-
-
Levi, F.1
Zidani, R.2
Misset, J.L.3
-
83
-
-
0037531121
-
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
-
Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21 (11): 2509-069
-
(2003)
J Clin Oncol
, vol.21
, Issue.11
, pp. 2509-3069
-
-
Rothenberg, M.L.1
Oza, A.M.2
Bigelow, R.H.3
-
84
-
-
0042213493
-
N9741:oxaliplatin (oxal) or CPT-11 +5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT11 in advanced colorectal cancer (CRC): Updated efficacy and quality of life data from an intergroup study
-
abstract no. 1009
-
Goldberg RM, Morton RF, Sargent D, et al. N9741:oxaliplatin (oxal) or CPT-11 +5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT11 in advanced colorectal cancer (CRC): updated efficacy and quality of life data from an intergroup study [abstract no. 1009]. Proc Am Soc Clin Oncol 2003; 22: 252
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
, pp. 252
-
-
Goldberg, R.M.1
Morton, R.F.2
Sargent, D.3
-
85
-
-
0027314411
-
Microsatellite instability in cancer of the proximal colon
-
Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260 (5109): 816-9
-
(1993)
Science
, vol.260
, Issue.5109
, pp. 816-819
-
-
Thibodeau, S.N.1
Bren, G.2
Schaid, D.3
-
86
-
-
0001120708
-
Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer
-
Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer. Proc Am Soc Clin Oncol 2002
-
(2002)
Proc Am Soc Clin Oncol
-
-
Grothey, A.1
Deschler, B.2
Kroening, H.3
-
87
-
-
0003226922
-
FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer: Final results of a phase III study
-
abstract no. 494
-
Tournigand C, Louvet C, Quinax E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer: final results of a phase III study [abstract no. 494]. Proc Am Soc Clin Oncol 2001; 21
-
(2001)
Proc Am Soc Clin Oncol
, vol.21
-
-
Tournigand, C.1
Louvet, C.2
Quinax, E.3
-
88
-
-
0025312728
-
A genetic model for colorectal tumorigenesis
-
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61 (5): 759-67
-
(1990)
Cell
, vol.61
, Issue.5
, pp. 759-767
-
-
Fearon, E.R.1
Vogelstein, B.2
-
89
-
-
0036175062
-
Emerging pathways in colorectal-cancer development
-
Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002; 3 (2): 83-8
-
(2002)
Lancet Oncol
, vol.3
, Issue.2
, pp. 83-88
-
-
Haydon, A.M.1
Jass, J.R.2
-
90
-
-
0034642605
-
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
-
Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342 (2): 69-77
-
(2000)
N Engl J Med
, vol.342
, Issue.2
, pp. 69-77
-
-
Gryfe, R.1
Kim, H.2
Hsieh, E.T.3
-
91
-
-
0033831989
-
Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer
-
Wright CM, Dent OF, Barker M, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000; 87 (9): 1197-202
-
(2000)
Br J Surg
, vol.87
, Issue.9
, pp. 1197-1202
-
-
Wright, C.M.1
Dent, O.F.2
Barker, M.3
-
92
-
-
0034690610
-
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
-
Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355 (9217): 1745-50
-
(2000)
Lancet
, vol.355
, Issue.9217
, pp. 1745-1750
-
-
Elsaleh, H.1
Joseph, D.2
Grieu, F.3
-
93
-
-
0038002279
-
Tumor microsatellite instability (MSI) status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
-
Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite instability (MSI) status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349 (3): 247-57
-
(2003)
N Engl J Med
, vol.349
, Issue.3
, pp. 247-257
-
-
Ribic, C.M.1
Sargent, D.J.2
Moore, M.J.3
-
94
-
-
0034087575
-
Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
-
Edler D, Hallstrom M, Johnston PG, et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000; 6 (4): 1378-84
-
(2000)
Clin Cancer Res
, vol.6
, Issue.4
, pp. 1378-1384
-
-
Edler, D.1
Hallstrom, M.2
Johnston, P.G.3
-
95
-
-
0036534108
-
Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
-
Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20 (7): 1721-8
-
(2002)
J Clin Oncol
, vol.20
, Issue.7
, pp. 1721-1728
-
-
Edler, D.1
Glimelius, B.2
Hallstrom, M.3
-
96
-
-
0030883708
-
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
-
Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15 (10): 3223-9
-
(1997)
J Clin Oncol
, vol.15
, Issue.10
, pp. 3223-3229
-
-
Leichman, C.G.1
Lenz, H.J.2
Leichman, L.3
-
97
-
-
0033975032
-
Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients
-
Paradiso A, Simone G, Petroni S, et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000; 82 (3): 560-7
-
(2000)
Br J Cancer
, vol.82
, Issue.3
, pp. 560-567
-
-
Paradiso, A.1
Simone, G.2
Petroni, S.3
-
98
-
-
0034048729
-
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
-
Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6 (4): 1322-7
-
(2000)
Clin Cancer Res
, vol.6
, Issue.4
, pp. 1322-1327
-
-
Salonga, D.1
Danenberg, K.D.2
Johnson, M.3
-
99
-
-
0035860142
-
A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
-
Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85 (6): 827-30
-
(2001)
Br J Cancer
, vol.85
, Issue.6
, pp. 827-830
-
-
Iacopetta, B.1
Grieu, F.2
Joseph, D.3
-
100
-
-
0035750549
-
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
-
Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1 (1): 65-70
-
(2001)
Pharmacogenomics J
, vol.1
, Issue.1
, pp. 65-70
-
-
Pullarkat, S.T.1
Stoehlmacher, J.2
Ghaderi, V.3
-
101
-
-
0037144354
-
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation
-
Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002; 101 (3): 253-8
-
(2002)
Int J Cancer
, vol.101
, Issue.3
, pp. 253-258
-
-
Van Kuilenburg, A.B.1
Meinsma, R.2
Zoetekouw, L.3
-
102
-
-
0034808681
-
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
-
Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7 (9): 2832-9
-
(2001)
Clin Cancer Res
, vol.7
, Issue.9
, pp. 2832-2839
-
-
Raida, M.1
Schwabe, W.2
Hausler, P.3
-
103
-
-
0029973215
-
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
-
Wei X, McLeod HL, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98 (3): 610-5
-
(1996)
J Clin Invest
, vol.98
, Issue.3
, pp. 610-615
-
-
Wei, X.1
McLeod, H.L.2
McMurrough, J.3
-
104
-
-
0031912432
-
Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
-
Lu Z, Zhang R, Carpenter JT, et al. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4 (2): 325-9
-
(1998)
Clin Cancer Res
, vol.4
, Issue.2
, pp. 325-329
-
-
Lu, Z.1
Zhang, R.2
Carpenter, J.T.3
-
105
-
-
0034892379
-
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
-
Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7 (8): 2182-94
-
(2001)
Clin Cancer Res
, vol.7
, Issue.8
, pp. 2182-2194
-
-
Mathijssen, R.H.1
Van Alphen, R.J.2
Verweij, J.3
-
106
-
-
0036025450
-
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
-
Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2 (1): 43-7
-
(2002)
Pharmacogenomics J
, vol.2
, Issue.1
, pp. 43-47
-
-
Iyer, L.1
Das, S.2
Janisch, L.3
-
107
-
-
0014439920
-
The natural history of primary and secondary malignant tumors of the liver 1: The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy
-
Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver 1: the prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969; 23: 198-202
-
(1969)
Cancer
, vol.23
, pp. 198-202
-
-
Bengmark, S.1
Hafstrom, L.2
-
108
-
-
0032696758
-
Surgical therapy of hepatic colorectal metastasis
-
Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999; 49 (4): 231-55
-
(1999)
CA Cancer J Clin
, vol.49
, Issue.4
, pp. 231-255
-
-
Fong, Y.1
-
109
-
-
0035105338
-
Surgical treatment of hepatic and pulmonary metastases from colon cancer
-
Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001; 71 (3): 975-9
-
(2001)
Ann Thorac Surg
, vol.71
, Issue.3
, pp. 975-979
-
-
Headrick, J.R.1
Miller, D.L.2
Nagorney, D.M.3
-
110
-
-
1642468237
-
Adjuvant therapy after resection of liver-limited colorectal cancer metastases
-
Dec; San Francisco (CA)
-
Goldberg RM. Adjuvant therapy after resection of liver-limited colorectal cancer metastases. ASCO 2000 Clinical Practice Forum; 2000 Dec; San Francisco (CA); 73-7
-
(2000)
ASCO 2000 Clinical Practice Forum
, pp. 73-77
-
-
Goldberg, R.M.1
-
111
-
-
0344051547
-
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer: Meta-Analysis Group in Cancer
-
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer: Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996; 88 (5): 252-8
-
(1996)
J Natl Cancer Inst
, vol.88
, Issue.5
, pp. 252-258
-
-
-
112
-
-
0033619892
-
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
-
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341 (27): 2039-48
-
(1999)
N Engl J Med
, vol.341
, Issue.27
, pp. 2039-2048
-
-
Kemeny, N.1
Huang, Y.2
Cohen, A.M.3
-
113
-
-
0037087721
-
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy: An intergroup study
-
Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy: an intergroup study. J Clin Oncol 2002; 20 (6): 1499-505
-
(2002)
J Clin Oncol
, vol.20
, Issue.6
, pp. 1499-1505
-
-
Kemeny, M.M.1
Adak, S.2
Gray, B.3
-
114
-
-
0032791959
-
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
-
Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10 (6): 663-9
-
(1999)
Ann Oncol
, vol.10
, Issue.6
, pp. 663-669
-
-
Giacchetti, S.1
Itzhaki, M.2
Gruia, G.3
-
115
-
-
0001407135
-
Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR)
-
abstract no. 504
-
Saltz L, Meropol NJ, Loehrer PJ, et al. Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) [abstract no. 504]. Proc Am Soc Clin Oncol 2002; 21
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Saltz, L.1
Meropol, N.J.2
Loehrer, P.J.3
-
116
-
-
0037208589
-
Phase II, randomized trial comparing Bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing Bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21 (1): 60-5
-
(2003)
J Clin Oncol
, vol.21
, Issue.1
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
-
117
-
-
0043177668
-
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC
-
abstract no. 3646
-
Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract no. 3646]. Proc Am Soc Clin Oncol 2003; 22
-
(2003)
Proc Am Soc Clin Oncol
, vol.22
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Cartwright, T.3
|